Glenmark Pharmaceuticals wins USFDA nod for fluticasone inhaler

Glenmark Pharmaceuticals has secured a significant approval from the US FDA for its inhaler fluticasone propionate. This marks a key step in strengthening the company's respiratory offerings in the US market. The product is set for distribution starting March. Glenmark's achievement includes a Competitive Generic Therapy designation, granting them 180 days of market exclusivity.